Overview

The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions

Status:
Not yet recruiting

Trial end date:
2022-05-03

Target enrollment:

Participant gender:

Summary

The study is designed in accordance with the Eurasian Economic Union (EAEU) regulatory guidelines, with the aim of characterizing the bioavailability of two pharmaceutical products of sunitinib in healthy adult volunteers. Within the clinical portion of the study, each volunteer will receive a single oral dose of the test and the reference product in compliance with the generated randomization code.

Phase:

Phase 1

Details

Lead Sponsor:

JLLC NatiVita

Collaborator:

National Anti Doping Laboratory, Belarus

Treatments:

Sunitinib